This Patient Information has been approved by the U.S. Food and Drug Administration. | Issued: September 2018 | |
PATIENT INFORMATION VIZIMPRO (vih-ZIM-pro) (dacomitinib) tablets | ||
What is VIZIMPRO? VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic):
It is not known if VIZIMPRO is safe and effective in children. | ||
Before taking VIZIMPRO, tell your healthcare provider about all your medical conditions, including if you:
| ||
How should I take VIZIMPRO?
| ||
What should I avoid during treatment with VIZIMPRO?
| ||
What are the possible side effects of VIZIMPRO? VIZIMPRO may cause serious side effects, including:
| ||
|
| |
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||
How should I store VIZIMPRO?
| ||
General information about the safe and effective use of VIZIMPRO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VIZIMPRO for a condition for which it was not prescribed. Do not give VIZIMPRO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about VIZIMPRO that is written for health professionals. | ||
What are the ingredients in VIZIMPRO? Active ingredient: dacomitinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. Film coating contains: Opadry II Blue 85F30716 containing: Polyvinyl alcohol – partially hydrolyzed, Talc, Titanium dioxide, Macrogol/PEG 3350, and FD&C Blue #2/Indigo Carmine Aluminum Lake. LAB-1238-1.0 For more information, go to www.VIZIMPRO.com or call 1-800-438-1985. |
This Patient Information has been approved by the U.S. Food and Drug Administration. | Issued: September 2018 | |
PATIENT INFORMATION VIZIMPRO (vih-ZIM-pro) (dacomitinib) tablets | ||
What is VIZIMPRO? VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic):
It is not known if VIZIMPRO is safe and effective in children. | ||
Before taking VIZIMPRO, tell your healthcare provider about all your medical conditions, including if you:
| ||
How should I take VIZIMPRO?
| ||
What should I avoid during treatment with VIZIMPRO?
| ||
What are the possible side effects of VIZIMPRO? VIZIMPRO may cause serious side effects, including:
| ||
|
| |
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||
How should I store VIZIMPRO?
| ||
General information about the safe and effective use of VIZIMPRO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VIZIMPRO for a condition for which it was not prescribed. Do not give VIZIMPRO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about VIZIMPRO that is written for health professionals. | ||
What are the ingredients in VIZIMPRO? Active ingredient: dacomitinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. Film coating contains: Opadry II Blue 85F30716 containing: Polyvinyl alcohol – partially hydrolyzed, Talc, Titanium dioxide, Macrogol/PEG 3350, and FD&C Blue #2/Indigo Carmine Aluminum Lake. LAB-1238-1.0 For more information, go to www.VIZIMPRO.com or call 1-800-438-1985. |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.